Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Catalysis . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
This patent introduces a novel dual-chiral ligand enabling high enantioselectivity in asymmetric catalysis, offering significant cost reduction and supply chain reliability for API intermediates manufacturing.
Patent CN110452150B enables one-step synthesis of axial chiral indole-naphthalene compounds under mild conditions with high optical purity, offering significant cost reduction and reliable supply for pharmaceutical catalysis applications.
Novel axial chiral phosphine-ene ligand enables mild-condition asymmetric allylation with high yield and enantioselectivity, ensuring reliable supply chain for pharmaceutical intermediates.
Novel optically active bisphosphinylpyrazine derivative enables Markovnikov-selective hydroboration with enhanced enantioselectivity and simplified manufacturing process for pharmaceutical intermediates.
Novel phosphine ligands enable high-yield Markovnikov hydroboration with exceptional enantioselectivity while improving supply chain reliability for pharmaceutical intermediates.
Breakthrough axial chiral catalyst enables high-purity API intermediates with enhanced stereoselectivity and scalable manufacturing advantages.
Breakthrough chiral biaryl pyridoxamine catalyst enables high-yield asymmetric transamination with mild conditions, offering reliable supply chain for pharmaceutical intermediates.
Patent CN110452150B enables one-step asymmetric synthesis under mild conditions with exceptional optical purity, delivering significant cost reduction and supply chain reliability for chiral catalyst manufacturing.
Patent CN111848322B enables high-yield resolution of axially chiral compounds with >96% ee through mild organocatalysis, ensuring reliable supply chain performance for pharmaceutical intermediates.
Patent CN102746343B enables high-yield asymmetric synthesis of trifluoromethyl propargyl alcohols with >95% ee, reducing lead time and costs in pharmaceutical intermediate production.
Patent CN102659494A enables high-purity oxindole synthesis with mild conditions, reducing lead time and manufacturing costs for pharmaceutical intermediates.
Discover how novel axial chiral phosphine-ene ligands enable high-yield, enantioselective allyl substitutions with simplified manufacturing for pharma R&D and production.
Solve chiral synthesis challenges with metal-free helicene production. 99% ee, 68% yield. Reduce costs & supply risks for asymmetric catalysis.
Reduce supply chain risks with metal-free deracemization process. 90%+ yield, 95% ee, and scalable production for chiral alcohol intermediates.
Solve chiral synthesis challenges with 93% yield and 98:2 er. Our CDMO expertise scales this patent-protected method for stable API supply chains.
Solve chiral ligand supply chain risks with this metal-free synthesis. 86% yield, no resolution needed. Contact for custom production.
Solve high-cost chiral catalyst production with 99.5% ee, 80% yield, and no toxic reagents. Scale to 100MT/yr with NINGBO INNO PHARMCHEM.
Solve chiral induction challenges with 97% yield axial diamine synthesis. Reduce R&D costs & scale production for pharma intermediates.
Solve low-yield challenges in Balasubramide synthesis. 97% ee, 45% yield, no cytotoxicity. CDMO expertise for scalable production.
Discover how this novel axial chiral phosphine catalyst enables high-yield, high-enantioselective synthesis for pharmaceutical intermediates, reducing production costs and supply chain risks.